Dual function engineered t cells with hpv e6 specificity and pd-1 blockade
AssigneeTcrcure Biopharma Corp.
InventorsPin Wang, Si Li
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to engineered cells and compositions thereof, particularly, T cells comprising genetically engineered T Cell receptors (TCRs) and checkpoint inhibitors (CPIs). Methods for using the compositions to treat cancer are also disclosed herein. Genetically engineered T cells that recognize tumor antigen HPV E6 and simultaneously secrete a single-chain antibody that blocks Programmed Cell Death Protein 1 (PD-1). Also provided is an immunotherapy for HPV E6 expression related cancers.
Claims24
An engineered T cell, comprising:
- a nucleic acid encoding (a) genetically engineered antigen receptor that specifically binds to an antigen from HPV;
- and
- (b) an inhibitory protein that reduces function or expression of inhibitory receptors in a tumor.
A nucleic acid comprising (a) a nucleic acid encoding genetically engineered antigen receptor that specifically binds to an antigen from HPV;
- and (b) an inhibitory nucleic acid molecule that reduces the expression of an inhibitory receptor in a tumor.
A method of producing a genetically engineered T cell, comprising introducing a vector comprising 1) a nucleic acid encoding genetically engineered antigen receptor that specifically binds to a first antigen into a population of cells comprising T cells, the first antigen receptor specifically target to E6 receptor of HPV, (b) a nucleic acid molecule encoding an inhibitory protein capable of leading to a reduction of expression of PD-1 or PD-L1 and/or inhibiting upregulation of PD-1 or PD-L1 in T cells in the population upon incubation under one or more conditions.
Dependencies are inferred from the claim text.